Use of fluorodeoxyglucose-positron emission tomography
(FDG-PET) imaging has gained an increasing importance
in oncological applications. PET/computerized tomography
(CT) scan provides both anatomic and functional imaging.
FDG-PET/CT is used for staging of gynecological tumors,
evaluating response to treatment and detecting relapses. It has
been proven that FDG-PET/CT is useful for both early and advanced
stages of cervical cancer. It gives promising results in
determining prognoses and demonstrating recurrence foci in
the case of indefinable increased tumor markers existing after
treatment. As a diagnostic tool, PET/CT provides an important
benefit in patients with ovarian cancer with an increase
in the specific biomarker, CA-125, and negative findings on
conventional imaging. It has been emphasized that PET/CT
has an important role in endometrial cancer. Alternative PET
tracers are used for diagnosis of genital system cancers. In this
paper, we review the literature on the current role and future
contributions of PET imaging in gynecologic tumor imaging,
with particular attention on PET/CT.
Keywords: Fluorodeoxyglucose F18; gynecological cancers; positron emission tomography
